Intensity Therapeutics, Inc. (INTS) Analysis

Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.

Did some DD on a bunch of Biotech companies over the weekend, and this one stood out far above the rest. They are a clinical-stage biotech company focused on developing novel treatments for cancer, specifically their flagship product identified as INT230-6. As part of my DD, I evaluated the executives in charge of the company, and I was impressed by the team running this one. Compared to other companies at similar price ranges, they seem highly qualified across most major areas. Decades of exp...

Intensity Therapeutics, recently given an average price target of $3 by four analysts. Intensity Therapeutics (Nasdaq: INTS) is a **late‑stage clinical biotechnology company** based in Shelton, Connecticut. The firm is advancing **INT230‑6**, a proprietary intratumoral immuno-oncology therapy formulated on its **DfuseRx™ platform**—a system combining two cytotoxic agents (cisplatin, vinblastine) with a penetration-enhancing amphiphile (SHAO), enabling deep diffusion into solid tumors and trigge...

Although low volume it has great potential. This is mine only bio stock I have been investing in . Small moves , but steady. Now it has opportunity to move . Next goal $1 - Cash runway extended into the second half of 2026 - Regains NASDAQ minimum stockholders equity requirements as of yesterday - upgraded from Hold to buy $3 - In the INVINCIBLE-4 Study, patients receiving INT230-6 prior to the start of standard of care achieved high levels of tumor necrosis in 8 days - INT230-6 achieved ...